Cyno Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 10-12-2024
- Paid Up Capital ₹ 0.50 M
as on 10-12-2024
- Company Age 31 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.60 M
as on 10-12-2024
- Revenue %
(FY 2023)
- Profit -317.99%
(FY 2023)
- Ebitda -317.99%
(FY 2023)
- Net Worth -14.46%
(FY 2023)
- Total Assets -14.46%
(FY 2023)
About Cyno Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹0.60 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Madhu Jain, Sanjay Jain, and Rajendra Singh serve as directors at the Company.
- CIN/LLPIN
U24232RJ1993PLC007771
- Company No.
007771
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Oct 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Bharatpur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cyno Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhu Jain  | Director | 08-Oct-1998 | Current |
| Sanjay Jain | Director | 28-Sep-1998 | Current |
| Rajendra Singh | Director | 08-Oct-1998 | Current |
Financial Performance and Corporate Structure Insights of Cyno Pharmaceuticals.
Cyno Pharmaceuticals Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 317.99% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cyno Pharmaceuticals?
In 2023, Cyno Pharmaceuticals had a promoter holding of 99.20% and a public holding of 0.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Cyno Lifesciences Private LimitedActive 2 years 10 months
Madhu Jain and Sanjay Jain are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 18 Sep 1999 | ₹0.60 M | Satisfied |
How Many Employees Work at Cyno Pharmaceuticals?
Unlock and access historical data on people associated with Cyno Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cyno Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cyno Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
